Literature DB >> 6128770

Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats.

B H Hirst, J M Conlon, D H Coy, J Holland, B Shaw.   

Abstract

The gastric exocrine inhibitory activities of somatostatin-28 (SS-28) and somatostatin-14 (SS-14) were determined in conscious cats prepared with gastric fistulae. Gastric acid and pepsin secretions were stimulated with pentagastrin. Expressed in terms of exogenous doses, SS-14 (ID50: 1.49 nmol . kg-1 . h-1) was 3.4 times more potent than SS-28 (ID50: 5.12 nmol . kg-1 . h-1) as an inhibitor of gastric acid secretion. Similarly SS-14 (ID50: 0.25 nmol . kg-1 . h-1) was 3.8 times more potent than SS-28 (ID50: 0.96 nmol . kg-1 . h-1) as an inhibitor of pepsin secretion. Expressed in terms of circulating plasma concentration measured by radioimmunoassay, SS-14 (ID50: H+, 232 and pepsin 73 pM) was 8-9 times more potent than SS-28 (ID50: H+, 2112 and pepsin, 611 pM) as an inhibitor of gastric exocrine secretions. The plasma immunoreactive half-life of SS-28 (6.1 min) was double that for SS-14 (2.4 min) possibly due to a slower theoretical metabolic clearance rate of the larger peptide (30 and 87 ml . kg-1 . min-1, respectively). Both peptides had similar apparent distribution volumes (SS-14, 306 and SS-28, 263 ml . kg-1). As judged by gel chromatography of plasma samples, there was no evidence for the conversion of SS-28 to SS-14 in vivo. The reduced activity of SS-28, compared with SS-14, against gastric exocrine secretions contrasts with its more potent effects in the pituitary and pancreas.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128770     DOI: 10.1016/0167-0115(82)90115-x

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

Review 1.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

Review 2.  Pepsinogen.

Authors:  B I Hirschowitz
Journal:  Postgrad Med J       Date:  1984-11       Impact factor: 2.401

Review 3.  Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use.

Authors:  E Hanisch; J Doertenbach; K H Usadel
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Circulating somatostatin. Physiological regulator of pancreatic function?

Authors:  K Gyr; C Beglinger; E Köhler; U Trautzl; U Keller; S R Bloom
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  Characterization of somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium.

Authors:  W Feniuk; J Dimech; P P Humphrey
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 7.  Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity.

Authors:  Georgina L Thompson; Meritxell Canals; Daniel P Poole
Journal:  Front Pharmacol       Date:  2014-11-28       Impact factor: 5.810

8.  Medical management of gastrinoma in a cat.

Authors:  Michael Lane; Jeanne Larson; Silke Hecht; M Katherine Tolbert
Journal:  JFMS Open Rep       Date:  2016-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.